Separation of Asparagine-Linked (N-Linked) Oligosaccharides from Human Polyclonal IgG Using the CarboPac PA200 Column

Significance of the Topic

The detailed characterization of N-linked oligosaccharides is essential for ensuring the safety, efficacy and consistency of glycoprotein therapeutics and industrial products. High-resolution profiling supports quality control, batch comparability and structural elucidation of complex glycans derived from monoclonal and polyclonal antibodies.

Objectives and Study Overview

This study evaluates the performance of the newly introduced CarboPac PA200 column for separating N-linked oligosaccharides released from human polyclonal IgG. Key goals include comparing its resolution against the established PA100 column and demonstrating the use of sequential exoglycosidase digestions (neuraminidase, β-galactosidase) to assign glycan structures.

Methodology and Instrumentation

Human polyclonal IgG was deglycosylated using PNGase F (glycerol-free) or endoglycosidase H. The released glycans were analyzed by high-performance anion-exchange chromatography with pulsed amperometric detection (HPAE-PAD) on a Dionex ICS-3000 system. Separation conditions:

• Column: CarboPac PA200 analytical (3 × 250 mm) with PA200 guard (3 × 50 mm)
• Eluents: A = 100 mM NaOH; B = 100 mM NaOH/0.5 M sodium acetate
• Gradient: 0–5 min (99% A), 5–60 min (1→36% B)
• Flow rate: 0.5 mL/min; Column temp: 30 °C; PAD with disposable Au electrode
• Injection: 9 µL; Run time: 75 min (plus re-equilibration)

Used Instrumentation

• Dionex ICS-3000 chromatography system (SP pump, DC detector, autosampler)
• Chromeleon 6.8 software
• SpeedVac evaporator, centrifuge, vacuum pump for eluent preparation

Main Results and Discussion

The PA200 column delivered significantly sharper peaks and improved resolution of bovine fetuin oligosaccharide standards and human IgG glycans compared to the PA100. Reduced bead size and lower flow rate cut eluent consumption by half and enhanced online desalting. Exoglycosidase sequencing:

• Neuraminidase treatment identified peaks containing mono- and di-sialylated glycans, confirming exclusive release of N-acetylneuraminic acid (Neu5Ac) from human IgG.
• β-Galactosidase digestion revealed biantennary structures with terminal galactose and residual GlcNAc branches.
• Sequential desialylation and degalactosylation allowed assignment of fucosylation and branch-specific modifications.

Use of glycerol-free PNGase F was critical to prevent column overload and peak broadening observed with glycerol-containing enzyme preparations.

Benefits and Practical Applications

• Enhanced resolution for complex glycan profiles, especially from polyclonal and monoclonal antibodies.
• Reduced waste and lower eluent costs support greener operations.
• Improved desalting efficiency facilitates direct aqueous injections.
• Enables robust lot-to-lot comparability and structural assignment via exoglycosidase mapping.

Future Trends and Opportunities

Further optimization of hydroxide concentration (e.g. up to 250 mM NaOH) could yield additional resolution gains. Integration with mass spectrometry and automated data analysis pipelines will streamline glycan characterization. Development of more sustainable gradients and miniaturized columns may enhance throughput and reduce environmental impact.

Conclusion

The CarboPac PA200 column represents a significant advancement in HPAE-PAD glycan analysis, delivering superior resolution, lower solvent consumption and robust performance for profiling N-linked oligosaccharides. Its compatibility with exoglycosidase sequencing methods provides a powerful toolset for detailed glycan structural characterization.

Reference

1. Hardy MR, Townsend RR. Proc Natl Acad Sci USA 1988, 85, 3289–3293.
2. Dionex Application Note 67, 2003.
3. Dionex Technical Note 42, 1997.
4. Hardy M, Rohrer JS. In Comprehensive Glycoscience; Elsevier, 2007; Vol.2, pp.303–327.
5. Dionex Application Update 150, 2005.
6. Dionex Technical Note 21, 1998.
7. Dionex Technical Note 71, 2007.
8. Weitzhandler M et al. J Pharm Sci 1994, 83, 1670–1675.
9. Rohrer JS. Glycobiology 1995, 5, 359–360.
10. Cooper GA, Rohrer JS. Anal Biochem 1995, 226, 182–184.